ABSTRACT
Objective: To investigate the effect of protein transduction domain-oligomerization domain-hemagglutinin (PTD-OD-HA) fusion proteins on tumorigenic ability of chronic myeloid leukemia (CML) BaF3-P210 cells in mice. Methods: The untreated BaF3-P210 cells and BaF3-P210 cells treated with 40 μmol/L PTD-OD-HA for 48 h were injected into BALB/c mice through the tail vein, respectively. The general status and survival time of mice in each group were observed. The number of peripheral white blood cells (WBCs) was counted. The Wright-Giemsa-stained blood and bone marrow smears were examined. The pathological changes of liver, spleen and lung tissues were observed by HE staining. The expression level of bcr/abl protein in bone marrow cells from mice was determined by Western blotting. Results: The incidence rates of CML in mice in the untreated BaF3-P210 cell group and the PTD-ODHA-treated BaF3-P210 cell group were 90% (9/10) and 80% (8/10), respectively; WBCs counts in the two groups were (44.3±4.8)×109/L and (20.6±3.2) ×109/L (P<0.05), respectively; the expression levels of bcr/abl protein in bone marrow cells in the two groups were 5.13±0.46 and 1.32±0.29 (P<0.05), respectively. The average survivals in the untreated BaF3-P210 cell group and the PTD-OD-HA-treated BaF3-P210 cell group were (101.3±6.2) d and (185.4±8.7) d (P<0.05), respectively. Wright-Giemsa staining showed that the infiltration degree of leukemic cells in bone marrow, liver and spleen was lower in the PTD-OD-HA-treated BaF3-P210 cell group than that in the untreated BaF3-P210 cell group. Conclusion: PTD-OD-HA can inhibit the tumorigenic ability of CML with BaF3-P210 cells in BALB/c mice. Copyright© 2011 by TUMOR.